{"denoms":[{"counts":[{"groupId":"BG000","value":"70"}],"units":"Participants"}],"groups":[{"description":"E-Ld refers to the combination of Elotuzumab with Lenalidomide/Dexamethasone.","id":"BG000","title":"E-Ld"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.40","value":"67.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}],"title":"< 75 years"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":">= 75 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"35"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"62"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"32"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"2"}]}],"description":"ECOG is a 6-item scale used to discern patient status by rating categories such as disease progression, daily functioning, appropriate treatment, and prognosis. Performance status is scored on a scale ranging from 0-5, with (best score) 0=fully active and able to carry on all pre-disease performance without restriction and (worst score) 5=death.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"All Treated Participants"}